Timothy H Barclay1, Raymond D Barclay2. 1. Liberty University, Department of Psychology, 1971 University Blvd. Lynchburg, VA 24502, United States. Electronic address: thbarclay@liberty.edu. 2. Stetson University, 421 N. Woodland Blvd. DeLand, FL 32723, United States. Electronic address: rbarclay@stetson.edu.
Abstract
BACKGROUND:Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process. Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression. This study used a randomized, double-blind, sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov, NCT01533415. METHODS:One hundred and fifteen participants, age 18 years and over, with a primary diagnosis of an anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and outcome measures at weeks one, three, and five. Response to treatment was defined as a reduction of ≥50% or more on these measures. RESULTS: Analysis of covariance revealed a significant difference between the active CES group and the sham CES group on anxiety (p=0.001, d=0.94) and on depression (p=0.001, d=0.78) from baseline to endpoint of study in favor of the active CES group. CONCLUSIONS:CES significantly decreases anxiety and comorbid depression. Subjects reported no adverse events during the study.
RCT Entities:
BACKGROUND:Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process. Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression. This study used a randomized, double-blind, sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov, NCT01533415. METHODS: One hundred and fifteen participants, age 18 years and over, with a primary diagnosis of an anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and outcome measures at weeks one, three, and five. Response to treatment was defined as a reduction of ≥50% or more on these measures. RESULTS: Analysis of covariance revealed a significant difference between the active CES group and the sham CES group on anxiety (p=0.001, d=0.94) and on depression (p=0.001, d=0.78) from baseline to endpoint of study in favor of the active CES group. CONCLUSIONS: CES significantly decreases anxiety and comorbid depression. Subjects reported no adverse events during the study.
Authors: Noah S Philip; Brent G Nelson; Flavio Frohlich; Kelvin O Lim; Alik S Widge; Linda L Carpenter Journal: Am J Psychiatry Date: 2017-02-24 Impact factor: 18.112
Authors: Shireen Patel; Clement Boutry; Priya Patel; Michael P Craven; Boliang Guo; Azhar Zafar; Joe Kai; David Smart; Debbie Butler; Fred Higton; Rebecca McNaughton; Paul M Briley; Chris Griffiths; Neil Nixon; Kapil Sayal; Richard Morriss Journal: Trials Date: 2022-04-04 Impact factor: 2.279
Authors: Deimante McClure; Samantha C Greenman; Siva Sundeep Koppolu; Maria Varvara; Zimri S Yaseen; Igor I Galynker Journal: J Nerv Ment Dis Date: 2015-11 Impact factor: 2.254